Helus Pharma Inc. (HELP)

$7.73 -1.24 (-13.82%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 864,772
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology
Sector: Healthcare
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
Framingtheworld
Framingtheworld Feb. 26 at 9:58 PM
$HELP I sold because $ATAI is better and they dropped. Re buy at $6.50
1 · Reply
cambruck7
cambruck7 Feb. 26 at 9:48 PM
$HELP
0 · Reply
Mastacash
Mastacash Feb. 26 at 9:30 PM
$HELP stock just had one of the best days in its history. And I’m the only one on this board. This is insane. We just retested the 200dma on a down day in the market and sector, and we bounced and closed green. I don’t think you realize how bullish that is. This is one of the best opportunities in the market. I’m buying like crazy while there is no volume, meaning there is Zero fast money in this name. Don’t worry, they will come in and be posting all over X and here once the stock is over $20, AND over a billion market cap. FYI I have buy orders way lower too. Incase we get a low volume sell off on data release.
2 · Reply
Mastacash
Mastacash Feb. 26 at 8:37 PM
$HELP so under the radar. This thing is going to triple before any actual volume comes in. lol.
0 · Reply
Mastacash
Mastacash Feb. 26 at 4:00 PM
$HELP rubbing my eyes, I think I just saw help pull back and tap the 200ema to the penny and bounce. All while atai dumps on data release. Hmmm
2 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Feb. 26 at 12:32 PM
$ATAI Releases Major Clinical Pipeline News 📰 ATAI Life Sciences announced positive topline results from its exploratory Phase 2a clinical trial evaluating EMP-01 for the treatment of social anxiety disorder. Trial Overview and Key Findings 👉🏽Randomized, double-blind, placebo-controlled exploratory trial 👉🏽EMP-01 demonstrated encouraging efficacy signals in patients with social anxiety disorder 👉🏽Treatment was reported to be generally well tolerated Strategic Importance 👉🏽Supports continued advancement of EMP-01 into future clinical trials 👉🏽Strengthens ATAI’s position in psychedelic-inspired therapeutics 👉🏽Reinforces the company’s focus on innovative psychiatric treatments EMP-01 remains in early-stage development, but the positive Phase 2a data marks an important step forward in ATAI’s efforts to expand treatment options for social anxiety disorder. Communicated Disclaimer : https://bit.ly/3OCJhol Sector Peers: $GHRS $HELP $RLMD $SILO
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 26 at 11:18 AM
$HELP Share Price: $7.71 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.24 – $1.51 Potential Upside: 53% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
cambruck7
cambruck7 Feb. 25 at 8:14 PM
$HELP
0 · Reply
Ridethesqueeze
Ridethesqueeze Feb. 25 at 6:17 PM
$HELP puuuuuushhhhhh
0 · Reply
HelusPharmaIR
HelusPharmaIR Feb. 25 at 6:06 PM
$HELP Helus Pharma has appointed Dr. Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee. With more than 40 years of experience across clinical practice, academia, and global biopharma leadership, she will guide clinical development strategy, regulatory engagement, and translational rigor across our novel serotonergic agonist portfolio. This appointment further strengthens our governance framework as we advance late-stage programs. If you would like to know more, feel free to leave your questions below.
1 · Reply
Latest News on HELP
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Feb 24, 2026, 11:55 PM EST - 2 days ago

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 24, 2026, 7:45 AM EST - 2 days ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 17, 2026, 7:30 AM EST - 9 days ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Feb 13, 2026, 7:31 AM EST - 13 days ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 30, 2025, 3:33 PM EST - 2 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 2 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 3:11 PM EST - 3 months ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 3 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 3 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 4 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 4 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 4 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 4 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 4 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 5 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 3:59 PM EDT - 6 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 6 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 6 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 6 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 6 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 7 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 8 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 8 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 8 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 8 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 9 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 9 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 10 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 10 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 10 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 11 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Feb 10, 2025, 9:48 PM EST - 1 year ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 15, 2025, 12:07 PM EST - 1 year ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 5:00 PM EST - 1 year ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Framingtheworld
Framingtheworld Feb. 26 at 9:58 PM
$HELP I sold because $ATAI is better and they dropped. Re buy at $6.50
1 · Reply
cambruck7
cambruck7 Feb. 26 at 9:48 PM
$HELP
0 · Reply
Mastacash
Mastacash Feb. 26 at 9:30 PM
$HELP stock just had one of the best days in its history. And I’m the only one on this board. This is insane. We just retested the 200dma on a down day in the market and sector, and we bounced and closed green. I don’t think you realize how bullish that is. This is one of the best opportunities in the market. I’m buying like crazy while there is no volume, meaning there is Zero fast money in this name. Don’t worry, they will come in and be posting all over X and here once the stock is over $20, AND over a billion market cap. FYI I have buy orders way lower too. Incase we get a low volume sell off on data release.
2 · Reply
Mastacash
Mastacash Feb. 26 at 8:37 PM
$HELP so under the radar. This thing is going to triple before any actual volume comes in. lol.
0 · Reply
Mastacash
Mastacash Feb. 26 at 4:00 PM
$HELP rubbing my eyes, I think I just saw help pull back and tap the 200ema to the penny and bounce. All while atai dumps on data release. Hmmm
2 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Feb. 26 at 12:32 PM
$ATAI Releases Major Clinical Pipeline News 📰 ATAI Life Sciences announced positive topline results from its exploratory Phase 2a clinical trial evaluating EMP-01 for the treatment of social anxiety disorder. Trial Overview and Key Findings 👉🏽Randomized, double-blind, placebo-controlled exploratory trial 👉🏽EMP-01 demonstrated encouraging efficacy signals in patients with social anxiety disorder 👉🏽Treatment was reported to be generally well tolerated Strategic Importance 👉🏽Supports continued advancement of EMP-01 into future clinical trials 👉🏽Strengthens ATAI’s position in psychedelic-inspired therapeutics 👉🏽Reinforces the company’s focus on innovative psychiatric treatments EMP-01 remains in early-stage development, but the positive Phase 2a data marks an important step forward in ATAI’s efforts to expand treatment options for social anxiety disorder. Communicated Disclaimer : https://bit.ly/3OCJhol Sector Peers: $GHRS $HELP $RLMD $SILO
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 26 at 11:18 AM
$HELP Share Price: $7.71 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.24 – $1.51 Potential Upside: 53% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
cambruck7
cambruck7 Feb. 25 at 8:14 PM
$HELP
0 · Reply
Ridethesqueeze
Ridethesqueeze Feb. 25 at 6:17 PM
$HELP puuuuuushhhhhh
0 · Reply
HelusPharmaIR
HelusPharmaIR Feb. 25 at 6:06 PM
$HELP Helus Pharma has appointed Dr. Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee. With more than 40 years of experience across clinical practice, academia, and global biopharma leadership, she will guide clinical development strategy, regulatory engagement, and translational rigor across our novel serotonergic agonist portfolio. This appointment further strengthens our governance framework as we advance late-stage programs. If you would like to know more, feel free to leave your questions below.
1 · Reply
ZRadly
ZRadly Feb. 25 at 5:32 PM
$HELP This ones been a money train since the early days. Flip Flip Flipinbehind the scenes has been very very profitable.... years of fun. GL😉...
0 · Reply
Mastacash
Mastacash Feb. 25 at 5:31 PM
$HELP after all this, it would be funny if helus ends up being “him”. It happens often actually, I made the same call on Onds last year, it surpassed all peers and is now sector leader. Honestly other than the stock performance and previous management dilution, there is little difference between helus and peers. You could say in many cases helus looks better.
2 · Reply
Basana09
Basana09 Feb. 25 at 5:29 PM
$HELP
0 · Reply
notatrol
notatrol Feb. 25 at 5:12 PM
$HELP volume coming in
0 · Reply
Orlandotrader
Orlandotrader Feb. 25 at 5:02 PM
$HELP Market finally realizes Stock is too cheap for Phase 2 getting ready to read out with Phase 3 later this year. Plenty of cash to support Trials.
1 · Reply
Jesstersg1
Jesstersg1 Feb. 25 at 1:33 AM
$HELP I just saw this stock in a wall street beat promo ad. Normally I ignore promos but this one is different I think? Have I finally landed at the right place at the right time? And will I have the patience to see real profits if it pans out? I hope so! I am coming in first thing Monday and buying 5k worth of dec call options. These options could go up 10,000% or so I'm guessing if this stock sees a bull tun to $50 this year. I have lost my azz over the years probably 750k a 5,000% bump on a 5k investment would be awesome. I wouldn't be making money yet. But it would sure feel like it. I never stick with my convictions! My mom died suddenly in 2022. I had accumulated 200k shares of rycey averaged in right around one dollar. I was all in and set to wait till 10 bucks let the other half ride. After finding mom dead in the driveway on a hot July day and I lost my mind started gambling wildly on penny stocks lost all but 10k.rycey went from one dollar to 18. I would be at 2.8 million now
3 · Reply
Not_Rico_Again_Jorge
Not_Rico_Again_Jorge Feb. 25 at 1:04 AM
$HELP How much is one ready to pay to rebuild credibility? A lot. A CGO makes no sense. Not sure why they have even opted for this title, which has no basis in th pharma/biotech world.
0 · Reply
a_rational_investor
a_rational_investor Feb. 24 at 11:52 PM
$HELP what a day! Congrats all
1 · Reply
BRITLS
BRITLS Feb. 24 at 10:58 PM
$HELP this move mostly based on the new hire?
0 · Reply
firetypecracker
firetypecracker Feb. 24 at 9:58 PM
$HELP Helus Pharma Names Former Pfizer CMO Freda Lewis-Hall to Board and Scientific Advisory Role Helus Pharma has appointed former Pfizer executive Dr. Freda Lewis-Hall to its board of directors and as chair of its Scientific Advisory Committee, bringing more than 40 years of experience in psychiatry, biopharmaceutical leadership, and public health. The move is expected to strengthen Helus’ clinical development strategy, regulatory engagement, and scientific governance as it advances its novel serotonergic agonist portfolio toward commercialization and seeks greater recognition in the mental health therapeutics market. Her appointment underscores the company’s emphasis on patient outcomes, disciplined execution, and long-term value creation for stakeholders as it builds its position in the psychiatric drug development landscape. The most recent analyst rating on $HELP +9.51% ▲ stock is a BUY with a $30.00 price target. https://www.tipranks.com/news/company-announcements/helus-pharma-names-former-pfizer-cmo-freda-lewis-hall-to-board-and-scientific-advisory-role
0 · Reply
Framingtheworld
Framingtheworld Feb. 24 at 9:19 PM
$ATAI $HELP coukd be a big winner too
0 · Reply
rml360
rml360 Feb. 24 at 9:04 PM
$HELP nice close
0 · Reply